CTOs on the Move

Trevi Therapeutics

www.trevitherapeutics.com

 
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Trevi Therapeutics raised $50.5M on 07/20/2017
Trevi Therapeutics raised $55M on 04/07/2022

Similar Companies

Global Pharmaceutical Corp

Global Pharmaceutical Corp is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthon Pharmaceuticals Inc

Synthon Pharmaceuticals Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iTherX

iTherX is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Falks Woodland Pharmacy

Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accumulus

Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.